Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer
A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 Gel to Clinically Noninfected Chronic Diabetic Foot Ulcers (cDFU)
Sponsor: Lakewood-Amedex Inc
Terminated
Request for additional preclinical data.
Other Chronic Diabetic Foot Ulcers trials with similar outcome
A PHASE2 clinical study on Chronic Diabetic Foot Ulcers, this trial is terminated or withdrawn. The trial is conducted by Lakewood-Amedex Inc and has accumulated 7 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Terminated PHASE2
-
Jul 2022 — Feb 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lakewood-Amedex Inc
- PrimeVigilance
- Professional Education and Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .